200 related articles for article (PubMed ID: 32057799)
1. The selective 5-HT
Fisher R; Hikima A; Morris R; Jackson MJ; Rose S; Varney MA; Depoortere R; Newman-Tancredi A
Neuropharmacology; 2020 May; 167():107997. PubMed ID: 32057799
[TBL] [Abstract][Full Text] [Related]
2. The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
McCreary AC; Varney MA; Newman-Tancredi A
Neuropharmacology; 2016 Jun; 105():651-660. PubMed ID: 26777281
[TBL] [Abstract][Full Text] [Related]
3. NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H; McCreary AC; Varney MA; Kleven MS; Koek W; Bardin L; Depoortère R; Cenci MA; Newman-Tancredi A
Exp Neurol; 2015 Sep; 271():335-50. PubMed ID: 26037043
[TBL] [Abstract][Full Text] [Related]
4. The selective 5-HT
Depoortere R; Johnston TH; Fox SH; Brotchie JM; Newman-Tancredi A
Parkinsonism Relat Disord; 2020 Sep; 78():151-157. PubMed ID: 32846366
[TBL] [Abstract][Full Text] [Related]
5. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
[TBL] [Abstract][Full Text] [Related]
6. The dopamine D(2) receptor partial agonist aplindore improves motor deficits in MPTP-treated common marmosets alone and combined with L-dopa.
Jackson MJ; Andree TH; Hansard M; Hoffman DC; Hurtt MR; Kehne JH; Pitler TA; Smith LA; Stack G; Jenner P
J Neural Transm (Vienna); 2010 Jan; 117(1):55-67. PubMed ID: 19809864
[TBL] [Abstract][Full Text] [Related]
7. Effects of the Serotonin 5-HT
Newman-Tancredi A; Varney MA; McCreary AC
Neurochem Res; 2018 May; 43(5):1035-1046. PubMed ID: 29572645
[TBL] [Abstract][Full Text] [Related]
8. Activity of serotonin 5-HT(1A) receptor 'biased agonists' in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.
Iderberg H; McCreary AC; Varney MA; Cenci MA; Newman-Tancredi A
Neuropharmacology; 2015 Jun; 93():52-67. PubMed ID: 25645393
[TBL] [Abstract][Full Text] [Related]
9. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia.
Bézard E; Muñoz A; Tronci E; Pioli EY; Li Q; Porras G; Björklund A; Carta M
Neurosci Res; 2013 Dec; 77(4):242-6. PubMed ID: 24135129
[TBL] [Abstract][Full Text] [Related]
10. GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Iravani MM; Costa S; Jackson MJ; Tel BC; Cannizzaro C; Pearce RK; Jenner P
Eur J Neurosci; 2001 Feb; 13(3):597-608. PubMed ID: 11168568
[TBL] [Abstract][Full Text] [Related]
11. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
Hamadjida A; Nuara SG; Gourdon JC; Huot P
J Neural Transm (Vienna); 2018 Sep; 125(9):1355-1360. PubMed ID: 29247391
[TBL] [Abstract][Full Text] [Related]
12. The highly selective 5-HT
Hamadjida A; Nuara SG; Bédard D; Gaudette F; Beaudry F; Gourdon JC; Huot P
Neuropharmacology; 2018 Sep; 139():61-67. PubMed ID: 29969592
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the differential roles of striatal 5-HT
Meadows SM; Chambers NE; Conti MM; Bossert SC; Tasber C; Sheena E; Varney M; Newman-Tancredi A; Bishop C
Exp Neurol; 2017 Jun; 292():168-178. PubMed ID: 28342749
[TBL] [Abstract][Full Text] [Related]
14. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
[TBL] [Abstract][Full Text] [Related]
15. Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.
Jackson MJ; Swart T; Pearce RK; Jenner P
J Neural Transm (Vienna); 2014 Feb; 121(2):163-9. PubMed ID: 23959162
[TBL] [Abstract][Full Text] [Related]
16. NLX-112, a highly selective 5-HT
Depoortère R; Bergman J; Beardsley PM; Desai RI; Paronis CA; Walentiny DM; Varney MA; Newman-Tancredi A
Neuropharmacology; 2022 Jun; 210():109025. PubMed ID: 35276118
[TBL] [Abstract][Full Text] [Related]
17. Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
Sid-Otmane L; Hamadjida A; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Michaud V; Beaudry F; Panisset M; Huot P
Eur J Pharmacol; 2020 Apr; 873():172957. PubMed ID: 32004527
[TBL] [Abstract][Full Text] [Related]
18. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
[TBL] [Abstract][Full Text] [Related]
19. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.
Johnston TH; Geva M; Steiner L; Orbach A; Papapetropoulos S; Savola JM; Reynolds IJ; Ravenscroft P; Hill M; Fox SH; Brotchie JM; Laufer R; Hayden MR
Mov Disord; 2019 May; 34(5):708-716. PubMed ID: 30575996
[TBL] [Abstract][Full Text] [Related]
20. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
